Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 2 CSU enrollment completion expected in Q3 2023 -- Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 -- Phase 2 EoE study expected to initiate...
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 29, 2023 09:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune &...
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
February 28, 2023 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics,...
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
February 26, 2023 09:00 ET
|
Celldex Therapeutics, Inc.
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class addition to a historically limited...
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
February 16, 2023 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased...
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
February 15, 2023 07:00 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma...
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
February 03, 2023 07:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic...
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
December 06, 2022 06:00 ET
|
Celldex Therapeutics, Inc.
- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients -- Long term follow up of patients with chronic inducible...
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
December 02, 2022 09:31 ET
|
Celldex Therapeutics, Inc.
- Includes oral presentation for 1.5 mg/kg cold urticaria cohort - - Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET - HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) --...
Celldex to Participate in Upcoming November Investor Conferences
November 10, 2022 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in...